
Erika J Crosby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4728343/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight, 2019, 4, .	5.0	77
2	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncolmmunology, 2018, 7, e1421891.	4.6	57
3	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clinical Cancer Research, 2019, 25, 2725-2736.	7.0	50
4	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy. Clinical Cancer Research, 2021, 27, 2481-2493.	7.0	33
5	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research, 2020, 26, 4670-4681.	7.0	31
6	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
7	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
8	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight, 2022, 7, .	5.0	14
9	Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Therapy, 2023, 30, 794-802.	4.6	8
10	HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Molecular Cancer Research, 2021, 19, 1699-1711.	3.4	5
11	Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. Oncotarget, 2021, 12, 1-3.	1.8	2
12	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. Molecular Cancer Therapeutics, 2022, 21, 217-226.	4.1	2